Skip to main content
Premium Trial:

Request an Annual Quote

Clarient, Acorn Team Up on Tumor Molecular Testing

NEW YORK (GenomeWeb News) – GE Healthcare company Clarient and Acorn Research today announced a collaboration targeting the molecular testing of tumor samples.

The collaboration, the terms of which were not disclosed, brings together Clarient's expertise in cancer diagnostics and Acorn's oncology network and advanced bioinformatics platform, they said.

The firms will create standardized testing protocols across the Acorn network of oncology community practices and hospitals "with treatment guidelines and clinical trial opportunities," in the hope of delivering individualized targeted treatments based on specific genetic markers. A system for collecting tumor specific biomarker data when patients are initially diagnosed with cancer will also be established.

The collaboration, the firms said, will enable the matching of biomarker data with outcomes data for clinical trials and clinical practice to identify new prognostic biomarkers and biomarker-specific treatments.

Discovering new biomarkers that could lead to the treatment of cancer on an individualized basis "has the potential to improve mortality rates, enhance patient quality of life, and reduce the cost of burden on cancer treatment to both patients and payers," Ron Andrews, CEO of Clarient, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more